Differential regulation of arylamine and arylalkylamine N-acetyltransferases in human retinoblastoma (Y-79) cells

For the first time, arylamine and arylakylamine N-acetyltransferase (NAT) activities are shown to be differentially regulated. In a human retinoblastoma (Y-79) cell line, arylalkylamine NAT activity, but not arylamine NAT activity increased (3-5-fold) rapidly (1-3 h) in response to treatment with dibutyryl cAMP. In contrast, treatment with butyrate showed a delayed (3-5 days) increase (3-5-fold) in arylamine NAT activity but not in arylalkylamine NAT activity. The differential response to these agents in Y-79 cells provides a model system for future studies on the regulatory relationship between the two enzyme activities.